AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca has recently completed a Phase 1 clinical study titled ‘A Phase 1, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer.’ The study aimed to evaluate the safety and tolerability of AZD9833, a promising treatment for endocrine-resistant ER+ HER2- breast cancer, which is not suitable for curative treatment. This study is significant as it explores new therapeutic options for a challenging cancer type.
The intervention being tested is AZD9833, an experimental drug administered orally. It is designed to target and treat advanced breast cancer in Japanese women, specifically those with ER+ HER2- profiles.
The study employed an open-label, single-group design with no masking, focusing primarily on treatment. It enrolled up to 18 participants across two cohorts to assess the drug’s safety and anti-tumor activity.
Key dates for the study include its start on September 29, 2020, and its last update on August 6, 2025. These dates are crucial as they mark the study’s timeline and its progression towards completion.
The completion of this study could positively impact AstraZeneca’s stock performance by enhancing investor confidence in their oncology pipeline. As the company continues to innovate in cancer treatment, it positions itself strongly against competitors in the pharmaceutical industry.
The study is completed, and further details are available on the ClinicalTrials portal.